Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Canada

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

Orphan indication? No easy access

Health technology assessment for orphan drugs continues to present challenges for pharmaceutical companies

- PMLiVE

Infographic: Orphan drug market

A visual guide to the orphan drug and rare disease market for pharma

Interview: Beate Wieseler, IQWIG

Head of the department of drug assessment at the German HTA body on taking a pragmatic approach to comparing medicines

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

- PMLiVE

IMS Health acquires HGS Europe

Founders Graeme and Angela McFarlane bring HGS' market access services to IMS' UK team

EU flag

EMA drug data to address HTA needs

EU regulator agrees joint work plan with EUnetHTA

UK flag

NHS medicine spend to remain flat for two years

But UK drug pricing deal stops short of PPRS overhaul to value-based system

Interview: Allan Hillgrove, Boehringer

Boehringer’s head of sales and marketing on access, partnerships and China on an important year for the German pharma company

Putin – pharma’s friend or foe in Russia?

Assessing the opportunities and challenges for pharmaceutical companies entering the Russian market

- PMLiVE

NICE backs Roche’s MabThera in rare autoimmune disease

Overturns previous negative draft guidance from England's cost-effectiveness body

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links